Phase 2 study of the anti-angiogenesis agent AG-013736 as second- or later-line treatment in patients with advanced non-small cell lung cancer.

Trial Profile

Phase 2 study of the anti-angiogenesis agent AG-013736 as second- or later-line treatment in patients with advanced non-small cell lung cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2012

At a glance

  • Drugs Axitinib (Primary)
  • Indications Cancer metastases; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Feb 2012 Additional location (Germany) added as reported by ClinicalTrials.gov.
    • 11 Oct 2007 The expected completion date for this trial is now 1 Jul 2007.
    • 04 Oct 2007 Status change from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top